We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Randox Laboratories

  Platinum Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App





Randox Showcases Latest Product Portfolio and Services at MEDLAB Middle East 2021

By LabMedica International staff writers
Posted on 23 Jun 2021
Print article
Image: Randox Showcases Latest Product Portfolio and Services at MEDLAB Middle East 2021 (Photo courtesy of Randox Laboratories)
Image: Randox Showcases Latest Product Portfolio and Services at MEDLAB Middle East 2021 (Photo courtesy of Randox Laboratories)
Randox Laboratories (Crumlin, UK) shared a wealth of new products and innovative technologies with the industry at the 2021 edition of MEDLAB Middle East.

Randox has developed a range of new tests for COVID-19 (SARS-CoV-2) targeting genes in line with WHO & CDC recommendations. Utilizing Patented Biochip Technology, with results available from the Vivalytic, Evidence Investigator and Randox Discovery, capable of detecting both SARS-CoV-2 and Sarbecovirus (confirmatory target), to report SARS-CoV-2 positive patient samples. The Vivalytic, Evidence Investigator and Randox Discovery platforms were on display at this year’s MEDLAB Middle East.

Randox also showcased its new benchtop lab - Randox Discovery - an exciting and unique analyzer consolidating molecular and immunoassay workflows onto one compact benchtop platform. The COVID-19 diagnostic analyzer is the first to combine sample preparation techniques including extraction, PCR & Biochip Technology. Simple and easy to use, the intuitive user-interface guides the operator through the entire testing process. Built with the user and laboratory in mind, a single operator is all that is required to run up to three fully automated discovery platforms increasing operator walkaway time and ensuring rapid turnaround time of three hours to first batch results.

In addition, Randox presented the RX series of clinical chemistry analyzers that offer the world’s most extensive dedicated clinical chemistry test menu comprising routine chemistries, specific proteins, lipids, therapeutic drugs, drugs of abuse, antioxidants, veterinary and diabetes testing. They guarantee real cost savings through consolidation of routine and specialized tests onto a single platform. The RX series analyzers - RX MISANO, RX MONACO, RX DAYTONA+,

RX IMOLA and RX MODENA - deliver excellence in patient care, offering unrivalled precision with excellent reagent CV ranges, providing laboratories with the upmost reliability, analyser uptime and accuracy of patient results. With their extensive test menu and versatile range of analyzers, the RX series presents the ultimate in performance, functionality and efficiency with testing capabilities to suit all laboratory sizes and types. Renowned for robust hardware and intuitive software, the RX series continues to revolutionize testing in a variety of laboratory types including; Clinical Laboratories, University & Research Institutes, Veterinary Laboratories and Food & Wine Testing Laboratories.

Related Links:
Randox Laboratories

Automated ELISA-IFA-BLOT Processor AP 22
New
Gold Supplier
Auto Urinary Sediment Analyzer
EH-2030
New
Microtiter Strip Reader
HumaReader Single plus
New
Semi-Auto Urine Test Strip Analyzer
HTI CL-50 Plus

Print article

Channels

Molecular Diagnostics

view channel
Image: A new method reliably detects protein changes in blood that are typical of Parkinson`s disease (Photo courtesy of Pexels)

First-Ever Blood Test Detects Parkinson’s Disease

Until now, the diagnosis of Parkinson's disease has been based primarily on typical movement disorders such as muscle stiffness, slower movements and shaking. However, the disease starts up to 20 years... Read more

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.